Nasacort AQ gains expanded pediatric use
Sanofi-aventis's Nasacort AQ (triamcinolone acetonide nasal spray) has been approved for the treatment of seasonal and perennial allergic rhinitis in children 2–5 years of age. This approval was based on a double-blind, placebo-controlled study involving 464 children where those receiving Nasacort AQ showed significant improvement in the combined symptoms of sneezing, itching, runny nose and congestion, compared with placebo.
Nasacort AQ is already available for the treatment of seasonal and perennial allergic rhinitis in patients ≥6 years of age.
For more information call (800) 446-6267 or visit www.nasacortaq.com.